Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|August 2, 2015
- Pharmaceutical Technology-08-02-2015
- Volume 39
- Issue 8
Mass Spectrometer Improves Efficiency
Shimadzu’s LCMS-8060 triple quadrupole mass spectrometer is designed for LC/MS/MS quantitation of highly sensitive applications.
Shimadzu’s LCMS-8060 triple quadrupole mass spectrometer is designed for LC/MS/MS quantitation of highly sensitive applications and can detect substances at ultra-trace levels as they occur in complex matrices or in small sample concentrations that must be diluted to avoid matrix effects. The newly developed UF-Qarray ion guide increases sensitivity by enhancing ion signal intensity and reducing noise. In addition, the LCMS-8060 has an increased data-acquisition scan speed of 30,000 u/sec and a polarity switching time of 5 msec. The faster polarity switching time maximizes dwell times and helps to optimize cycle time.
Shimadzu
Articles in this issue
about 11 years ago
Getting Comfortable With Leanabout 11 years ago
Black Specks in Tablet Stability Samplesabout 11 years ago
Environmental Containment Performance—Is There Accountability?about 11 years ago
Implementing Electronic Production Recordsabout 11 years ago
Understanding Risks in Pharmaceutical Shippingabout 11 years ago
Outsourcing Becoming More Cost Competitiveabout 11 years ago
Regulation of Medical Devices and Companion Diagnosticsabout 11 years ago
Campaign Against Fake Drugs Gains Momentumabout 11 years ago
Defining Crucial CAPA Componentsabout 11 years ago
Taking the Pulse of Manufacturing Trends and Equipment UseRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.